Hyperion DeFi, Inc. (HYPD)
| Market Cap | 64.26M |
| Revenue (ttm) | 67,063 |
| Net Income (ttm) | -42.38M |
| Shares Out | 5.10M |
| EPS (ttm) | -34.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 792,064 |
| Open | 10.99 |
| Previous Close | 10.79 |
| Day's Range | 10.40 - 12.82 |
| 52-Week Range | 0.85 - 124.80 |
| Beta | 2.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2025 |
About HYPD
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. ... [Read more]
Financial Performance
In 2024, Hyperion DeFi's revenue was $57,336, an increase of 1414.02% compared to the previous year's $3,787. Losses were -$49.82 million, 82.7% more than in 2023.
Financial StatementsNews
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
NEW YORK , June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a serie...
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy
Eyenovia Surges on Crypto Announcement
Eyenovia shares more than doubled as the company entered a $50 million investment agreement and said it plans to launch a hyperliquid cryptocurrency treasury reserve strategy.
Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
Announces private placement EYEN to become first U.S.-based publicly listed company to hold HYPE in its treasury Hyunsu Jung appointed Chief Investment Officer and Board Member LAGUNA HILLS, Calif., J...
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol ® water-free drug delivery technology for glaucoma with Eyenovia's Optejet ® device platform
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® ...
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provide...
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this ...
Eyenovia Announces 1-for-80 Reverse Stock Split
Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Revers...
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders m...
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of th...
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging i...
Eyenovia Provides Update on Restructuring Efforts
Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet ...
Eyenovia to discontinue late-stage study for eye drug
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Pa...
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular...
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized use...
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in deve...
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information New market research shows strong interest from ophthalmic surgeons fol...
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new opht...